Company
San Francisco
Every investor coverage indicates participated in a round Alta Partners raised.
Companies Alta Partners acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Alta Partners. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
ChemGenex has signed a convertible note deal giving Cephalon up to A$15 million in notes, plus options over 19.9 percent of shares held by Stragen and Merck; major shareholders back the issue.
Also GBS Ventures
Opal Therapeutics partners with Massachusetts General Hospital on an HIV immunotherapy collaboration as human trials begin in London; the biotech counts Alloy Ventures, Alta Partners and GBS Ventures among its backers.
ChemGenex completed an A$10.5m rights issue following an equal February institutional placement, a combined A$21m raise, with Alta Partners and GBS Venture Partners increasing their stakes to fund Ceflatonin leukemia trials.
Biotech Proacta's release: its Phase I cancer-drug trial is underway, and Alta Partners' new funding tops the Series A up to $12M alongside lead backer GBS Ventures; Alta's David Mack joins the board.
OPAL Therapeutics raised a US$6 million Series A, with GBS Venture Partners leading a syndicate including Alloy Ventures, Alta Partners and Uniseed, to develop HIV and hepatitis C immunotherapies from University of Melbourne technology.